linjc16/ctgov huggingface dataset:
DBT and Escitalopram in Borderline Personality Disorder

Study Overview
=================
Brief Summary
-----------------
Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Official Title
-----------------
Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder

Conditions
-----------------
Borderline Personality Disorder

Intervention / Treatment
-----------------
* Behavioral: Dialectical Behavioral Therapy
* Drug: Escitalopram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is a male or female between 18 and 60 who meets criteria for Borderline Personality Disorder and has been off psychotropic medications for at least 2 weeks (6 weeks for fluoxetine). - Exclusion Criteria: Meets criteria for Schizophrenia, Bipolar Disorder, Mental Retardation, current or recent Substance Dependence or a current Major Depressive Episode. Subjects also should not currently be in individual psychotherapy. (Case management and work therapy programs are allowed.) -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Dialectical Behavioral Therapy|nan|
|Drug: Escitalopram|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measures of impulsivity, aggression, affective impulsivity, immediate and delayed memory, and cognitive processing at baseline, 6 months and 9 months |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BPD, Borderline Personality Disorder, Dialectical Behavior Therapy, DBT, Escitalopram, Lexapro
Treatment of Hemorrhoid With 1940nm Laser Procedure

Study Overview
=================
Brief Summary
-----------------
Patients with hemorrhoids 2-3 st will be treated with laser 1940nm or sclerothearapy with Aethoxysklerol

Detailed Description
-----------------
Prospective randomized, control study. Patients with hemorrhoids 2-3 will be randomized in two groups. 100 patient in each. Patients will be treated with laser 1940nm or sclerothearapy with Aethoxysklerol. Follow up for one year. Primary end point - recurrence of hemorrhoids desease.

Official Title
-----------------
Treatment of Hemorrhoid With 1940nm Laser Procedure

Conditions
-----------------
Hemorrhoids

Intervention / Treatment
-----------------
* Procedure: laser procedure
* Procedure: sclerotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hemorrhoids 2-3st Exclusion Criteria: Acute hemorrhoids IBD psychosomatic diseases previous surgical interventions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Patients with hemorrhoids 2-3st will be randomized in two groups
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Laser 1940nm<br>Patients with hemorrhoidal deasease 2-3 st. who will be treated with laser 1940nm | Procedure: laser procedure<br>* In modified litothomy position patients with hemorrhoidal deasease will be treated with transcutaneous laser 1940nm 3watt in impulse regimen<br>|
| Active Comparator: sclerotherapy<br>Patients with hemorrhoidal deasease 2-3 st. who will be treated with sclerotherapy | Procedure: sclerotherapy<br>* In modified litothomy position patients with hemorrhoidal deasease will be treated with sclerotherapy with Aethoxysklerol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reccurence rate | reccurence of hemorroids desease | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity | Score representing patient's current pain intensity Minimum: 0 (no pain) Maximum: 100 (very severe pain) | 7 days | 
| QoL | The SF-36 is often used as a measure of a person or population's quality of life (QOL) The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemorrhoids, laser, sclerotherapy
Quality of Life With Esophageal Stent Trial

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare, specialist nurse home visits in patients with inoperable cancer in the esophagus or cardia, who are palliated with Self Expanding Metal Stent, to standard patient contact with regards to quality of life, number and character of reinterventions and cost-effectiveness.

Detailed Description
-----------------
The aim of this study is to compare, specialist nurse home visits in patients with inoperable cancer in the esophagus or gastro-esophageal junction (cardia), who are palliated with Self Expanding Metal Stent, to standard patient contact with regards to quality of life, number and character of reinterventions and cost-effectiveness.

Official Title
-----------------
Prospective, Randomized Trial of the Effects on HRQoL, Cost-Utility and Reintervention Rate, of Nurse Home Visits, in Patients With SEMS Treated Malignant Disease in the Esophagus and Cardia.

Conditions
-----------------
Esophageal Cancer, Gastro-esophageal Junction Cancer

Intervention / Treatment
-----------------
* Behavioral: Home visits
* Behavioral: standard


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Malignant obstruction of esophagus or cardia treated with SEMS due to non-operable disease. Exclusion Criteria: Mentally unable to fill out questionaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Home visit<br>After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse | Behavioral: Home visits<br>* home visits by specialist nurse 2 times and 1 phonecall<br>* Other names: pro active nurse care;|
| Active Comparator: Standard<br>Standard contact via Hotline and traditional referring methods | Behavioral: standard<br>* hotline<br>* Other names: After hours phone line;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HRQoL, EORTC C-30, EOS-18 |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Esophageal cancer, Cardia cancer, Health Related quality of Life, SEMS, Home visits
A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain

Study Overview
=================
Brief Summary
-----------------
This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication

Official Title
-----------------
Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain

Conditions
-----------------
Brain Pathology

Intervention / Treatment
-----------------
* Drug: Multihance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 yrs of age or older; provide written informed consent; scheduled to undergo MRI; willing to undergo 2 MRI exams within 14 days Exclusion Criteria: Known allergy to one or more ingredients in the test agents; severe CHF (Class IV); suffered stroke one year ago; pregnancy or lactating females; contraindications to MRI; severe claustrophobia; scheduled to receive surgery prior to or between the two MRI exams, or steroids or radiosurgery between the two MRI exams

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Multihance|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Superiority of Multihance in terms of by-patient global diagnostic performance |  | immediately post dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the two products in terms of by patients global performance for border delineation of lesions; contrast of lesions |  | immediately post dose | 
| To compare the two products in terms of global changes in lesion count; To compare the two products in terms of changes from pre to post dose in signal intensity |  | immediately post dose |
A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
The investigators describe a novel technique for GB fundus retraction.

Detailed Description
-----------------
few methods are available for gall bladder (GB) retraction in SILC to replace the usage of ancillary ports imitating retraction from conventional technique, e.g. trans-parietal stitches mini-loop retractor , a Kirschner wire . This technical note describes a novel way to retract the gall bladder fundus.

Official Title
-----------------
A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic Cholecystectomy

Conditions
-----------------
Gallbladder Diseases

Intervention / Treatment
-----------------
* Procedure: cholecystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all cases underwent single incision cholecystectomy Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cholecystectomy<br>single incision laparoscopic cholecystectomy | Procedure: cholecystectomy<br>* single incision laparoscopic cholecystectomy<br>* Other names: SILC;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| operative time | the time from starting the procedure till the skin closure | about 3 hours |
A Patient-Centric Platform Trial for Precision Oncology

Study Overview
=================
Brief Summary
-----------------
XCELSIOR is a non-interventional data registry. Information about treatments, treatment decisions and rationale, and patient outcomes including safety and effectiveness of anti-cancer therapy and associated supportive care will be collected for analysis.

Detailed Description
-----------------
XCELSIOR is patient-centric study for the registration of cancer patients, operations of a virtual tumor board, insight capture in clinical decision making, and collection of longitudinal, observational data in a cancer registry. Patient intake into XCELSIOR will occur through the Cancer Commons Web portal. This includes consent to participate in the data registry, including the collection and review of medical information by a Virtual Tumor Board, generation of patient-specific treatment options with supporting rationale, access to treatment access support services, and inclusion into a registry study that includes safety and efficacy outcomes tracking. Patients will be treated and tracked in their original treatment setting and the data generated will form part of a systematic framework combining expert judgment with artificial intelligence to maximize information gain and improve treatment option set development for individual cancer patients.

Official Title
-----------------
xCures/CancerCommons Enhanced Learning Treatment Selection and Analysis With Outcomes Research (XCELSIOR) Study: A Patient-Centric Platform Trial for Precision Oncology

Conditions
-----------------
Oncology

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both male and female patients with known or suspected recalcitrant or advanced cancer are eligible to enroll through the Cancer Commons Website Patients with any performance status, comorbidity or disease severity are eligible Patients or their legally-authorized representative must be willing and able to provide written, informed consent (and assent, if applicable) Exclusion Criteria: Patients must be a resident of or receiving care within the United States or US territories.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival (PFS) |  | 5 Years | 
| Overall Survival (OS) |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glioblastoma, Glioma, Pancreatic Adenocarcinoma
Unraveling the Klinefelter's Disease Physiopathology

Study Overview
=================
Brief Summary
-----------------
Organoid Model to unravel Klinefelter Syndrome infertility Klinefelter Syndrome (KS) is characterized by the presence of an extra chromosome X in male (47,XXY), it is the most frequent genetic cause of azoospermia in adult men. The investigators will isolate and expand spermatogonial cells from KS patients, then using an organoid model investigators will compare the behavior of these Spermatogonia from KS patients when interacting with four combinations of somatic cell types incorporated in the Extra Cellular Matrix hydrogel.

Detailed Description
-----------------
Men with Klinefelter Syndrome candidate for TESE or microTESE (testicular sperm extraction) for azoospermia. One extra testicular biopsy (1-2 mm) will be cryopreserved and used later for the cells isolation and culture.

Official Title
-----------------
Unraveling the Klinefelter's Disease Physiopathology by Organoid Model

Conditions
-----------------
Klinefelter Syndrome, Infertility, Male

Intervention / Treatment
-----------------
* Procedure: Testicular biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Klinefelter Exclusion Criteria: Mosaicism

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Infertile patients<br>Infertile patients going to surgery for fertility preservation or infertility treatment at University Clinic Saint-Luc Brussels | Procedure: Testicular biopsy<br>* Testicular biopsy is a clinical procedure for extraction of testicular tissue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Klinefelter's infertility physiopathology | Testicular biopsies will be digested using two steps enzymatic protocol. Cell suspensions will be in vitro cultured during 2 months. The following analyses will be performed: cells counts, cells characterisation by immunofluorescence and RTqPCR specific for the cell type, cells karyotypes. | Up to 60 days with intermediate time analyses at the 5th and 10 th passage of cultures. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Klinefelter Syndrome, fertility preservation, male
Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
We plan to investigate prospectively and simultaneously skin and blood DC subtypes, their donor/recipient origin and the correlation of DC reconstitution kinetics with treatment, clinical outcome and incidence of aGvHD in patients undergoing allogeneic hematopoietic stem cell transplantation.

Detailed Description
-----------------
Blood and skin DC reconstitution shall be investigated in patients affected by hematological diseases and receiving HLA-matched, mobilized peripheral blood stem cells from related or unrelated donors. We plan to simultaneously collect and process double biopsies, i.e. from graft versus host disease affected and non-lesional skin of patients at onset of acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Emigration assay, Chimerism analysis and immunohistochemistry will be performed.

Official Title
-----------------
Analysis of Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

Conditions
-----------------
Graft Versus Host Disease

Intervention / Treatment
-----------------
* Procedure: blood draw, skin shave biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient undergoing an allogeneic hematopoietic stem cell transplantation Older than 18 years WHO-Performance-Status 0 to3 Informed consent Graft versus host disease of the skin Exclusion Criteria: Clotting parameters more than double of normal Infection of the skin Leucocytes < 1000/µl; Thrombocytes < 20 000/µl

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: blood draw, skin shave biopsy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Graft versus host disease, Allogeneic hematpoietic stem cell transplantation
Patent Foramen Ovale Closure Reduce in SCUBA-divers

Study Overview
=================
Brief Summary
-----------------
It has been proposed that there would not be an increased risk of DCI after closure of the interatrial communication, i.e. patent foramen ovale (PFO).

Official Title
-----------------
Patent Foramen Ovale Closure Reduce in SCUBA-divers

Conditions
-----------------
Patent Foramen Ovale, Decompression Illness

Intervention / Treatment
-----------------
* Other: phone interviews


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: catheter-based PFO-closure because of DCI Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: phone interviews|phone interviews|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dives | Interview based on a questionnaire with questions focusing on the dive habits and DCI events. | 2017-01-01 until 2019-01-01 |